AI English summary of an SEC filing — figures as filed
Eli Lilly LLYEli Lilly said it entered into an underwriting agreement with Barclays Capital Inc., BofA Securities, Inc. and other 5 underwriters as representatives, to issue and sell 6 series of Notes maturing from 2028 to 2065. The filing is dated February 10, 2025.
Key points
AI summaryEli Lilly said it entered into an underwriting agreement with Barclays Capital Inc., BofA Securities, Inc. and other 5 underwriters as representatives, to issue and sell 6 series of Notes maturing from 2028 to 2065. The filing is dated February 10, 2025.
The company said it will issue Notes due 2028 at $1,000,000,000 (4.550%), due 2030 at $1,250,000,000 (4.750%), due 2032 at $1,000,000,000 (4.900%), due 2035 at $1,250,000,000 (5.100%), due 2055 at $1,250,000,000 (5.500%) and due 2065 at $750,000,000 (5.600%).
The company said it closed the offering of the Notes on February 12, 2025 and received net proceeds of about $6.46 billion, after deducting underwriting discounts and before estimated offering expenses payable by the company.
The company said interest on each series of Notes is payable 2 times a year, and the notes mature on February 12 in each year from 2028 through 2065. If an event of default occurs, the principal of the affected series may become immediately due and payable. The company may redeem all or part of the notes early on the applicable terms and conditions.
Summary
AI-writtenAnalysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Eli Lilly enters February 10, 2025 underwriting deal for 6 note series due 2028–2065
Eli Lilly said it entered into an underwriting agreement with Barclays Capital Inc., BofA Securities, Inc. and other 5 underwriters as representatives, to issue and sell 6 series of Notes maturing from 2028 to 2065. The filing is dated February 10, 2025.
Source · Based on the filing body and exhibits
Principal amounts and coupon rates by series
The company said it will issue Notes due 2028 at $1,000,000,000 (4.550%), due 2030 at $1,250,000,000 (4.750%), due 2032 at $1,000,000,000 (4.900%), due 2035 at $1,250,000,000 (5.100%), due 2055 at $1,250,000,000 (5.500%) and due 2065 at $750,000,000 (5.600%).
Source · Based on the filing body and exhibits
Eli Lilly closes offering on February 12, 2025, net proceeds about $6.46 billion
The company said it closed the offering of the Notes on February 12, 2025 and received net proceeds of about $6.46 billion, after deducting underwriting discounts and before estimated offering expenses payable by the company.
Source · Based on the filing body and exhibits
Interest payments, maturities, events of default and early redemption terms
The company said interest on each series of Notes is payable 2 times a year, and the notes mature on February 12 in each year from 2028 through 2065. If an event of default occurs, the principal of the affected series may become immediately due and payable. The company may redeem all or part of the notes early on the applicable terms and conditions.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…